1254199-54-6Relevant articles and documents
Discovery of the 3-Imino-1,2,4-thiadiazinane 1,1-Dioxide Derivative Verubecestat (MK-8931)-A β-Site Amyloid Precursor Protein Cleaving Enzyme 1 Inhibitor for the Treatment of Alzheimer's Disease
Scott, Jack D.,Li, Sarah W.,Brunskill, Andrew P. J.,Chen, Xia,Cox, Kathleen,Cumming, Jared N.,Forman, Mark,Gilbert, Eric J.,Hodgson, Robert A.,Hyde, Lynn A.,Jiang, Qin,Iserloh, Ulrich,Kazakevich, Irina,Kuvelkar, Reshma,Mei, Hong,Meredith, John,Misiaszek, Jeffrey,Orth, Peter,Rossiter, Lana M.,Slater, Meagan,Stone, Julie,Strickland, Corey O.,Voigt, Johannes H.,Wang, Ganfeng,Wang, Hongwu,Wu, Yusheng,Greenlee, William J.,Parker, Eric M.,Kennedy, Matthew E.,Stamford, Andrew W.
supporting information, p. 10435 - 10450 (2016/12/16)
Verubecestat 3 (MK-8931), a diaryl amide-substituted 3-imino-1,2,4-thiadiazinane 1,1-dioxide derivative, is a high-affinity β-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitor currently undergoing Phase 3 clinical evaluation for the treat
DIHYDROPYRIMIDINONES FOR USE AS BACE2 INHIBITORS
-
Page/Page column 37; 38, (2010/11/18)
This invention relates to dihydropyrimidinones of the formula (I), wherein X and R1 to R7 are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds are BACE2 inhibitors